JAK2 mutations in myeloproliferative neoplasms (MPNs) are associated with the germline GGCC (46/1) haplotype. In 2010, we reported an association between shortened survival in primary myelofibrosis (PMF) and nullizygosity for the JAK2 46/1 haplotype. In the current study, we have increased the number of informative cases from 130 to 414 (median age 63 years; 63% males), in order to revisit with the phenotypic and prognostic relevance of the JAK2 46/1 haplotype in PMF. JAK2 46/1 haplotype was documented in 69% of the study patients, including 25% in homozygous and 44% in heterozygous state. Driver mutation frequency in patients homozygous/heterozygous/nullizygous for the 46/1 haplotype was 78%/60%/56% JAK2, 10%/20%/18% type 1-like CALR, 3%/2%/5% type 2-like CALR, 4%/8%/7% MPL, and 6%/10%/14% triple-negative (P = .02). In univariate analysis, nullizygosity for the JAK2 46/1 haplotype was associated with inferior overall survival (HR 1.5, 95% CI 1.1-1.9), most pronounced in JAK2 (P <.001), as opposed to CALR/MPL mutated (P = .48) or triple-negative cases (P = .27). Multivariable analysis that included karyotype, driver mutational status and highmolecular risk mutations confirmed the independent prognostic contribution of nullizygosity for the 46/1 haplotype (P = .02; HR 1.4, 95% CI 1.1-1.8). Nullizygosity for 46/1 also remained significant in the context of the genetically-inspired GIPSS risk model (P = .04), but not in the context of the integrated genetics-clinical MIPSS70+ version 2.0 model (P = .4). Leukemia-free survival was not affected by the 46/1 haplotype (P = .6). The current study confirms the association of nullizygosity for the JAK2 GGCC (46/1) haplotype with inferior survival in JAK2-mutated PMF. we screened 130 patients with PMF for rs12343867 SNP (C/T), where the C allele tagged the JAK2 46/1 haplotype; genotype distributions in JAK2V617F mutated/unmutated cases were CC (homozygous) 31%/9%, CT (heterozygous) 38%/53%, and TT (nullizygous) 31%/38%. At the time, we unexpectedly discovered a
significant association between the TT genotype (ie, nullizygous for the JAK2 46/1 haplotype) and shortened survival in PMF, which was not accounted for by the international prognostic scoring system (IPSS) 8 or JAK2 mutant allele burden. 7 These observations were not validated by another study of 202 patients with PMF, where the investigators were not able to demonstrate phenotypic or prognostic distinctions across the three JAK2 46/1 haplotype profiles. 9 In this study, we have increased the number of informative PMF cases to 414 (from 130 we reported in 2010), in order to revisit with the phenotypic and prognostic relevance of the JAK2 46/1 haplotype in PMF. (WHO) criteria. 10 Clinical and laboratory information was retrospectively collected, corresponding to the time of first referral, which in the majority of cases was at the time of or within the first year of diagnosis. All patients were followed until death or last follow-up, as assessed by medical records or through direct contact with patients or their physicians. Data collection was updated as of April 2018.
| METHODS
Screening for the JAK2 46/1 haplotype included rs12343867 SNP genotyping, as previously detailed, 7 and using a commercially available TaqMan SNP genotyping assay (Applied Biosystems Inc., Foster City, California, USA). The determination of prognostically relevant mutations was made by next generation sequencing. 11, 12 Cytogenetics data were analyzed using standard techniques and reported in conformity with the International System for Human Cytogenetic Nomenclature criteria. 13 Prognostic models cited in the current study included dynamic IPSS (DIPSS), 14 the genetically inspired prognostic scoring system (GIPSS) 15 and the karyotype-and mutation-enhanced IPSS (MIPSS70+ version 2.0). 16, 17 Cytogenetic risk stratification for PMF was according to the recently revised model, which included favorable, unfavorable and very high risk (VHR) karyotype. 18 Sex-adjusted values for hemoglobin were applied in order to define anemia as severe (hemoglobin levels of <8 g/dL in women and <9 g/dL in men) or moderate (hemoglobin levels of 8-9.9 g/dL in women and 9-10.9 g/dL in men). 19 The Kaplan-Meier method was used to construct survival curves, which were compared by the log-rank test. P values of <0.05 were considered significant. The JMP Pro 13.0.0 software from SAS Institute, Cary, North Carolina, USA, was used for all calculations.
3 | RESULTS including 25% in homozygous and 44% in heterozygous state. Table 1 illustrates the clinical and laboratory comparisons between the JAK2 46/1 haplotype nullizygous vs heterozygous vs homozygous profiles.
| Presenting clinical and laboratory features
For the most part, the three haplotype states were phenotypically similar, including DIPSS (P = .1), GIPSS (P = .4) and MIPSS70+ version 2.0 risk distributions and the incidence of unfavorable and VHR karyotype (P = .4); the three haplotype states were also similar in the incidence of thrombotic events before and after diagnosis (Table 1) . On the other hand, there were some important differences; JAK2 46/1 haplotype homozygous/heterozygous/nullizygous distributions were 78%/60%/56% for JAK2, 10%/20%/18% for type 1-like CALR, 3%/2%/5% for type 2-like CALR, 4%/8%/7% for MPL and 6%/10%/14% for triple-negative status (P = .02); in other words, JAK2-mutated patients with PMF were more likely to display homozygous JAK2 46/1 haplotype while the converse was true for CALR type 1/like and triple-negative cases (Table 1 ). JAK2 46/1 homozygous ; n (%) 56 (14) 18 (14) 19 (10) 19 (18) 0.2
Circulating blasts %; median (range) "N" evaluable = 412
Circulating blasts ≥1 × 10 9 /L; n (%) "N" evaluable = 412
208 (50) 63 (50) 90 (49) 55 (53) 0.9
118 (29) 39 (31) 53 (29) 26 (25) (18) 31 (22) 13 (16) Low risk; n (%) 57 (18) 14 (14) 23 (16) 20 (25) (Continues) cases also displayed higher platelet (P = 0.02) and leukocyte (P = .003)
counts. Distribution of mutations other than JAK2/CALR/MPL was mostly similar among the three JAK2 46/1 haplotype states (Table 1) .
| Prognostic relevance of JAK2 46/1 haplotype status
In univariate analysis, the JAK2 46/1 haplotype status significantly affected survival, with the adverse effect primarily seen with the nullizygous state ( Figure 1A ; TT vs CC HR 1.4, 95% CI 1.02-1.8; TT vs CT HR 1.6, 95% CI 1.2-2.0); there was no difference in survival between homozygous (CC) and heterozygous (CT) JAK2 46/1 haplotype states (HR 0.9, 95% CI 0.7-1.2; Figure 1A ). Similarly, in 2-tiered classification, nullizygosity for the JAK2 46/1 haplotype was associated with inferior overall survival (HR 1.5, 95% CI 1.2-1.9; Figure 1B ). Other parameters displaying significance in univariate analysis included advanced age (both as a continuous and categorical variable), male gender, severe, and moderate anemia adjusted for sex, circulating blasts ≥2%, constitutional symptoms, VHR karyotype, unfavorable karyotype, absence of CALR type 1/like mutation and presence of ASXL1, SRSF2, and U2AF1 Q157 mutations (Table 2) .
Age-adjusted multivariable analysis confirmed the independent effect of the above-listed variables on survival (Table 2) ; in other words, the survival effect of nullizygosity for the JAK2 46/1 haplotype was independent of other prognostically-relevant genetic and clinical risk factors (Table 2 ). Of importance, the significant survival effect of nullizygosity for the JAK2 46/1 haplotype was sustained in the context of GIPSS (P = .04) but not in the context of MIPSS70+ version 2.0 (P = .4) ( Table 2) ; in order to further examine the loss of significance in the context of MIPSS70+ version 2.0, additional statistical analysis was performed and revealed significant association between nullizygosity for the JAK2 46/1 haplotype and constitutional symptoms (P = .03); the association with constitutional symptoms was also evident during separate analysis of JAK2 mutated cases (P = .05).
Most interesting was the observation that the adverse survival effect of nullizygosity for the JAK2 46/1 haplotype was most pronounced in JAK2 mutated cases ( Figure 1C ; HR 1.7, 95% CI 1.3-2.3), as opposed to CALR type 1/like (P = .7), CALR type 2/like (P = .8), or MPL (P = .6); borderline significance (P = .16) was noted for triplenegative cases. Based on this additional observation, the prognostic interaction between nullizygosity for the JAK2 46/1 haplotype and GIPSS (P = .03) and MIPSS70+ version 2.0 (P = .15) was re-examined (17) 23 (18) 36 (20) 10 (10) CALR type 2/like; n (%) 12 (3) 6 (5) 3 (2) 3 (3) MPL; n (%) 28 (7) 9 (7) 15 (8) 4 (4) Triple-negative; n (%) 43 (10) 18 (14) 19 (10) 6 (6) ASXL1 mutated ab ; n (%) "N" evaluable = 399
157 (39) 48 (40) 72 (41) 37 (37) 0.8
62 (15) 25 (20) 15 (8) 22 (22) 0.002
9 (3) 6 (6) 2 (1) 1 (1) 0.1
11 (3) 6 (6) 4 (3) 1 (1) 0.3
12 (4) 6 (6) 4 (3) 2 (3) 0.4
61 (15) 23 (19) 24 (14) 14 (14) 0.4
39 (10) 17 (14) 15 (8) 7 (7) 0.2 Allogeneic stem cell transplant; n (%) 33 (8) 6 (5) 21 (11) 6 (8) 0.08 Leukemic transformations; n (%) 61 (15) 17 (13) 30 (16) 14 (13) in patients with JAK2 mutated PMF, and revealed similar results.
Finally, leukemia-free survival was not affected by the JAK2 46/1 haplotype (P = .6).
| DISCUSSION
The current study (n = 414) confirms the association of nullizygosity for the JAK2 GGCC (46/1) haplotype with inferior survival in PMF.
The particular association was first recognized in a 2010 report (n = 130) 7 but was not confirmed by subsequent communications including 202 patients in one study 9 and 132 patients in another study. 22 The authors of one of these two latter studies 9 had suggested that differences in follow-up period, between the studies, might have contributed to the apparent discrepancy. Our observations from the current study encompassed additional details, including the possibility that the adverse survival effect of nullizygosity for the JAK2 46/1 haplotype might be limited to JAK2 mutated cases. In this regard, we and others have previously demonstrated the possible lack of an association between the JAK2 46/1 haplotype and nonJAK2 mutations and had suggested, therefore, that functional consequences of the JAK2 46/1 haplotype variant might not apply to other mutations, such as MPL. 23, 24 In this study, the observed survival effect of the JAK2 46/1 haplotype in patients with PMF was independent of currently acknowledged genetic risk factors, including karyotype and HMR mutations; consistently, its significance was also sustained in the context of the genetics based GIPSS risk model, regardless of whether or not the analysis included all 414 study patients or was limited to the 261 JAK2 mutated cases. 15 The loss of prognostic significance for the JAK2 46/1 haplotype state, in the context of MIPSS70+ version 2.0, 16 was also apparent when analysis was limited to JAK2 mutated cases and suggests an underlying prognostic interaction with nongenetic factors, including constitutional symptoms, possibly mediated by differential expression of cytokines.
Accurate information regarding causes of death was not available in the current study but the possibility of differences in leukemic transformation or thrombotic events was adequately addressed and found to be noncontributory. An association between the JAK2 46/1 haplotype and splanchnic as well as nonsplanchnic vein thrombosis in MPN has previously been reported. 25, 26 However, in this study, we found no significant associations with thrombotic events, carefully segregated into arterial vs venous events and timed before and after diagnosis. The lack of an association between leukemia-free survival and the JAK2 46/1 haplotype further supports the notion that the However, contrary to such suggestion, previous studies in patients with normal karyotype acute myeloid leukemia have instead implicated homozygous/heterozygous JAK2 46/1 haplotype as being associated with inferior survival, possibly related to increased risk of death from infection. 27 In an elegant editorial that accompanied the latter study, 27 Hermouet and Vilaine 28 entertained the possibility that the JAK2 46/1 haplotype might be a marker of myelomonocytic dysfunction and might also provide fertile ground for the acquisition of additional mutations.
From a practical standpoint, the GIPSS-independent survival effect of JAK2 46/1 haplotype raises the prospect of its inclusion in future genetics-based prognostic models for PMF. Obviously, our observations need independent validation from patient cohorts that must, however, secure adequate number of informative cases and a long enough follow-up period with a minimum of 50% of patients followed to death. At the same time, it is reasonable to question added value, in the context of a more comprehensive risk model, such as MIPSS70+ version 2.0. 16, 17 In this regard, the possible prognostic interaction with constitutional symptoms requires a prospective evaluation, including analysis of the recently unveiled cachexia index for PMF. 29 Whether or not the JAK2 46/1 haplotype influences survival or thrombosis risk in other MPN, or for that matter in the general population, remains to be investigated.
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